Natera, Inc. (NASDAQ:NTRA) Given Consensus Rating of “Buy” by Analysts

Shares of Natera, Inc. (NASDAQ:NTRA) have been assigned a consensus rating of “Buy” from the fifteen research firms that are currently covering the firm, Marketbeat.com reports. Fifteen analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last year is $98.47.

A number of equities research analysts recently weighed in on NTRA shares. Raymond James cut shares of Natera from a “strong-buy” rating to an “outperform” rating and lifted their price objective for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. Craig Hallum initiated coverage on shares of Natera in a research report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target on the stock. Robert W. Baird boosted their price target on shares of Natera from $99.00 to $117.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. The Goldman Sachs Group lifted their price target on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Finally, Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research note on Friday, April 5th.

Insider Activity at Natera

In related news, insider Daniel Rabinowitz sold 20,526 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $89.01, for a total value of $1,827,019.26. Following the completion of the sale, the insider now owns 204,218 shares of the company’s stock, valued at approximately $18,177,444.18. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Daniel Rabinowitz sold 20,526 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $89.01, for a total value of $1,827,019.26. Following the completion of the sale, the insider now directly owns 204,218 shares in the company, valued at approximately $18,177,444.18. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 1,028 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $88.36, for a total value of $90,834.08. Following the completion of the sale, the insider now owns 463,585 shares of the company’s stock, valued at $40,962,370.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 324,628 shares of company stock valued at $29,322,803. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its position in Natera by 28.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock worth $45,111,000 after purchasing an additional 159,993 shares during the period. Cerity Partners LLC lifted its position in Natera by 1,043.3% in the fourth quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock worth $5,664,000 after purchasing an additional 82,514 shares during the period. WCM Investment Management LLC raised its stake in Natera by 101.2% during the fourth quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock worth $9,058,000 after acquiring an additional 73,419 shares in the last quarter. Hamilton Lane Advisors LLC acquired a new position in Natera during the fourth quarter worth $616,000. Finally, abrdn plc acquired a new position in Natera during the fourth quarter worth $3,214,000. 99.90% of the stock is owned by institutional investors.

Natera Stock Performance

Shares of NTRA opened at $109.51 on Friday. Natera has a 1 year low of $36.90 and a 1 year high of $110.09. The company has a market cap of $13.45 billion, a price-to-earnings ratio of -35.10 and a beta of 1.38. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12. The firm has a fifty day moving average of $95.84 and a 200-day moving average of $75.92.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business had revenue of $367.70 million for the quarter, compared to analysts’ expectations of $316.31 million. During the same period in the previous year, the business earned ($1.23) earnings per share. The company’s revenue was up 52.1% on a year-over-year basis. As a group, equities analysts anticipate that Natera will post -2.44 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.